Provided consulting services to several early stage biotechs leveraging my expertise in immunooncology to contribute to the following advancements:
• Led the design and supervision of in vitro and in vivo pharmacology studies (Mono and combinatorial Immune Checkpoint inhibitor therapy, vaccine/antibody combo therapy, cell therapy)
• Scientific due diligence on combinatorial cancer immunotherapies (T cell targets, myeloid targets, Treg targets)
• Target and epitope identification for vaccines and TCR-T cell-based therapies
• Cancer vaccine design (Synthetic neoantigen vaccines, Multitope DC-based vaccines, GVax)
• Biomarker research (PD-L1 for PD-1/PD-L1 targeted antibody therapy; markers for TILs)
• Start-up strategy and pipeline development and management in the I/O space
• Tailor gene editing and gene delivery technologies to cell therapy modalities (T, NK, B, stem cells)

$2.2B public clinical stage biotech company focused on developing gene and cell therapies for genetic disorders, cancer and autoimmune disease.

$330M public, clinical stage biotech company focused on developing personalized vaccines, cell therapies and monoclonal antibodies for oncology indications.
● Director, In vivo Immuno-Pharmacology Led the in vivo Immuno-Pharmacology program, responsible for syngeneic, GEMM and humanized animal modeling for IP- and IND-driven preclinical R&D, spanning various hematological and solid malignancies. Manager and mentor to team of 2 direct and over 10 indirect scientists/research associates.
• Implemented novel approaches to combinatorial cancer immunotherapy (Combining antibodies targeting different components of the tumor microenvironment)
• Leader of various multi-disciplinary, cross-functional efforts pertaining to off-the-shelf and personalized cell therapies
• Vaccine platforms, adjuvants, immune checkpoint modulators (PD-1, CTLA-4, GITR, OX40, TIM3, LAG3 and others), and TCR-T and CAR-T cell-based immunotherapies and their combinations
• Leader in neoantigen-targeted vaccines (sh

• Oversaw a multidisciplinary translational research program in cancer immunology and immunotherapy
• Successfully completed research projects funded by the NCI Prostate SPORE, the Department of Defense CDMRP, the Prostate Cancer Foundation and Harvard Medical School
• Completed the preclinical phase of development of peptide-based vaccines in combination with immune checkpoint blockade and hormone therapy for the treatment of prostate cancer
• Completed preclinical evaluation of the safety and applicability of recombinant vaccinia and Live attenuated Listeria platforms for tumor vaccine delivery
• Genomics- and proteomics-based identification of putative tumor-associated antigens and biomarkers
• Implemented a bioinformatics-driven approach for biomarker identification and development of vaccines targeting tumor antigens and neo-antigens
• Identified novel mechanisms of hormone-induced immunosuppression in
● cells and developed new strategies to reverse them in conjunction with

• Initiated and advanced internal and multi-institutional collaborative projects aimed at comprehensive molecular profiling of lymphocyte and dendritic cell subsets in the context of tumor onset
• Identified key drivers (e.g. EGR2, PTPN1, FOXM1, MARCO, TIM1) of immune tolerance and designed strategies to counteract them to achieve immunomodulation of response to cancer vaccines
• Identified and validated several novel, putative prostate tumor-associated antigens (e.g. SIM2, SOX4, Myosin-VI) and mapped and tested their immunogenic determinants using a multi-step preclinical platform
• Used high throughput technologies to identify prostate cancer biomarkers in patients' serum and urine

• Investigated the role of class A scavenger receptors in regulating macrophage and dendritic cell interactions with pathogens in the lung, and their role in the modulation of infection, allergic asthma and ozone-induced pulmonary inflammation
• Established in vivo that scavenger receptors represent a key regulatory link between innate and adaptive immunity